| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 99.63 mm | 99.63 mm | 99.63 mm | 99.63 mm | 99.63 mm | 99.63 mm |
| Cash burn (monthly) | 91.33 k | 4.09 mm | 33.73 mm | 31.02 mm | 27.46 mm | 26.68 mm |
| Cash used (since last report) | 388.92 k | 17.42 mm | 143.65 mm | 132.10 mm | 116.91 mm | 113.61 mm |
| Cash remaining | 99.24 mm | 82.21 mm | -44.02 mm | -32.47 mm | -17.28 mm | -13.98 mm |
| Runway (months of cash) | 1086.5 | 20.1 | -1.3 | -1.0 | -0.6 | -0.5 |
| 13F holders | Current |
|---|---|
| Total holders | 177 |
| Opened positions | 17 |
| Closed positions | 34 |
| Increased positions | 66 |
| Reduced positions | 51 |
| 13F shares | Current |
|---|---|
| Total value | 359.67 bn |
| Total shares | 62.13 mm |
| Total puts | 209.00 k |
| Total calls | 364.00 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| BIIB Biogen | 6.24 mm | $539.95 mm |
| Vanguard | 5.76 mm | $41.59 bn |
| RTW Investments | 5.59 mm | $40.37 bn |
| BlackRock | 5.39 mm | $38.92 bn |
| FMR | 5.27 mm | $38.06 bn |
| BBBOF BB Biotech | 4.46 mm | $28.73 mm |
| BLVGF Bellevue | 4.46 mm | $32.21 bn |
| STT State Street | 2.93 mm | $21.13 bn |
| Millennium Management | 1.50 mm | $10.82 bn |
| Jacobs Levy Equity Management | 1.26 mm | $9.10 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Jan 25 | Laura Gault | Common Stock | Grant | Acquire A | No | No | 0 | 24,000 | 0.00 | 35,334 |
| 16 Jan 25 | Christopher Benecchi | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 44,737 |
| 16 Jan 25 | Christopher Benecchi | Stock Options Common Stock | Grant | Acquire A | No | No | 6.97 | 40,000 | 278.80 k | 40,000 |
| 16 Jan 25 | Gregory L. Shiferman | Common Stock | Grant | Acquire A | No | No | 0 | 14,000 | 0.00 | 33,888 |
| 16 Jan 25 | Gregory L. Shiferman | Stock Option Common Stock | Grant | Acquire A | No | No | 6.97 | 28,000 | 195.16 k | 28,000 |
| 16 Jan 25 | Barry E Greene | Stock Option Common Stock | Grant | Acquire A | No | No | 6.97 | 174,000 | 1.21 mm | 174,000 |
| 3 Jan 25 | George Golumbeski | Stock Options Common Stock | Grant | Acquire A | No | No | 6.14 | 13,593 | 83.46 k | 13,593 |
